The Look Of FDA’s Drug Safety Oversight Board
You may also be interested in...
FDA Taps NIH Veteran Corrigan-Curay To Lead Medical Policy Office
Jacqueline Corrigan-Curay joins from the National Heart, Lung and Blood Institute, where she worked on clinical trial initiatives and served as an NIH representative on FDA’s Drug Safety Oversight Board.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials